Expert consensus outlines perioperative immunotherapy protocols for hepatocellular carcinoma, highlighting standardized multidisciplinary clinical collaboration.
Immune checkpoint inhibitors (ICIs) have led to substantial advances in immunotherapy for hepatocellular carcinoma (HCC). Moreover, the use of ICI-based combination regimens for perioperative management of HCC has increased. To support clinicians in the rational, effective, and safe use of perioperative immunotherapy, the Hepatobiliary and Pancreatic Multidisciplinary Team Committee of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association, the Hepatic Surgery Group of the Surgery Branch of the Chinese Medical Association, the General Surgery Branch of the Chinese Society of Geriatric Medicine, and the Editorial Board of Chinese Journal of Digestive Surgery convened a multidisciplinary expert panel to develop the Chinese Multidisciplinary Expert Consensus on Perioperative Immunotherapy for Hepatocellular Carcinoma (2025 Edition). This consensus focuses on the principles and clinical applications of ICI-based immunotherapy in the perioperative setting for HCC. Accordingly, this review summarizes clinical recommendations based on the latest research to guide healthcare professionals involved in HCC management.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: